Vyant Bio (NASDAQ:VYNT) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research downgraded shares of Vyant Bio (NASDAQ:VYNTGet Rating) from a hold rating to a sell rating in a report published on Tuesday, Zacks.com reports.

According to Zacks, “VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J. “

Separately, HC Wainwright lowered their price target on shares of Vyant Bio from $5.00 to $4.00 and set a buy rating for the company in a report on Tuesday, March 8th.

NASDAQ VYNT traded up $0.01 on Tuesday, hitting $0.93. 1 shares of the stock were exchanged, compared to its average volume of 97,038. The company has a current ratio of 4.27, a quick ratio of 4.19 and a debt-to-equity ratio of 0.01. Vyant Bio has a fifty-two week low of $0.82 and a fifty-two week high of $4.24. The company has a 50-day moving average price of $1.14 and a 200-day moving average price of $1.48.

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in Vyant Bio by 6.9% during the 3rd quarter. Geode Capital Management LLC now owns 188,802 shares of the company’s stock worth $439,000 after buying an additional 12,122 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Vyant Bio during the 3rd quarter worth $254,000. Virtu Financial LLC purchased a new position in Vyant Bio during the 4th quarter worth $64,000. Morgan Stanley raised its position in Vyant Bio by 14,258.1% during the 2nd quarter. Morgan Stanley now owns 38,049 shares of the company’s stock worth $142,000 after buying an additional 37,784 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in Vyant Bio during the 2nd quarter worth $97,000. Hedge funds and other institutional investors own 8.71% of the company’s stock.

Vyant Bio Company Profile (Get Rating)

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).

Featured Stories

Get a free copy of the Zacks research report on Vyant Bio (VYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.